IP Library Granted Patent US 8,323,660
Granted Patent B2
US 8,323,660 · App. 12/853,074 · Granted Dec 4, 2012

Method for identification, isolation and production of antigens to a specific pathogen

Assignee: Intercell AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,323,660
App. No.
12/853,074
Granted
Dec 4, 2012
Kind
B2
Abstract

Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and—optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.

Claims (6)

1. A method of eliciting an immune response against Staphylococcus aureus comprising administering to a subject an effective amount of an isolated antigen comprising the sequence of SEQ ID NO: 142, or an antigenic fragment of SEQ ID NO. 142, wherein the antigenic fragment of SEQ ID NO: 142 comprises the sequence of one or more of amino acids 9-33, 56-62, 75-84, 99-105, 122-127, 163-180, 186-192, 206-228, 233-240, 254-262, 275-283, 289-296, 322-330, 348-355, 416-424, 426-438, 441-452, 484-491, 522-528, 526-544, 527-544, 541-549, 563-569, 578-584, 624-641, 1-42, 6-30, 18-42, 24-53, 209-244, 209-233, 218-244, 395-428, 395-418, 416-428, or 623-647 of SEQ ID NO. 142.

2. The method of claim 1 , wherein the antigenic fragment comprises at least 6 amino acids.

3. The method of claim 1 , wherein the antigenic fragment comprises at least 8 amino acids.

4. The method of claim 1 , further comprising administering an adjuvant to the subject.

5. The method of claim 1 , wherein the adjuvant is selected from the group consisting of polycationic peptides, immunostimulatory deoxynucleotides, alum, Freund's incomplete adjuvant, and human growth hormone.

6. The method of claim 1 , wherein the subject is human.

Priority Claims (1)
AT A 130/2001 · Jan 26, 2001 · national
Continuity (3)
Continuation 11614716 · Dec 21, 2006
Continuation 10470048
Related Publication 20110020402A1 · Jan 27, 2011